Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

Rhea-AI Summary

Benitec Biopharma (NASDAQ: BNTC) will host an Industry Forum Breakfast on March 10, 2026 at the MDA Clinical and Scientific Conference to present updated clinical results for BB-301, the only clinical-stage therapeutic in development for Oculopharyngeal Muscular Dystrophy (OPMD).

Benitec CEO Jerel A. Banks, M.D., Ph.D., will detail reported, durable improvements in dysphagia symptom burden and swallowing function observed in patients treated with low and high doses of BB-301. The session is open to registered conference attendees and virtually registered participants via MDA live stream.

Positive

• Durable improvement in dysphagia reported in Phase 1b/2a BB-301 patients
• BB-301 identified as the only clinical-stage therapeutic actively in development for OPMD
• Presentation of updated clinical results at MDA conference on March 10, 2026

Negative

• None.

News Market Reaction – BNTC

-2.23%

3 alerts

-2.23% News Effect

-8.2% Trough Tracked

-$10M Valuation Impact

$453M Market Cap

0.1x Rel. Volume

On the day this news was published, BNTC declined 2.23%, reflecting a moderate negative market reaction. Argus tracked a trough of -8.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $453M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Industry forum time: 7:00 a.m. – 8:00 a.m. ET

1 metrics

Industry forum time 7:00 a.m. – 8:00 a.m. ET BB-301 Industry Forum Breakfast on March 10, 2026

Market Reality Check

Price: $11.75 Vol: Volume 373,544 is 1.83x t...

high vol

$11.75 Last Close

Volume Volume 373,544 is 1.83x the 20-day average of 204,381, indicating elevated interest ahead of the BB-301 forum. high

Technical Shares at $12.55 are trading below the 200-day MA at $13.14 and about mid-range between the $9.85 52-week low and $17.15 high.

Peers on Argus

BNTC gained 10.67% while key biotech peers like AUTL and LRMR were up modestly a...

2 Up 1 Down

BNTC gained 10.67% while key biotech peers like AUTL and LRMR were up modestly and FULC was down. With no same-day peer news and mixed moves, BNTC’s strength appears company-specific rather than a broad sector rotation.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Clinical data update	Positive	+10.7%	Interim Phase 1b/2a data showing stronger high-dose BB-301 efficacy in OPMD.
Feb 23	Conference abstract	Positive	+0.8%	Late-breaking abstract acceptance for BB-301 interim data at MDA conference.
Feb 12	Earnings and update	Positive	-2.7%	Q2 FY2026 results with BB-301 responder data and planned FDA meeting.
Jan 11	Clinical trial results	Positive	+2.5%	Positive long-term BB-301 Phase 1b/2a efficacy and durability in OPMD.
Nov 14	Earnings and financing	Positive	+2.8%	Q1 FY2026 update with 100% responder rate, fast track, and $100M equity raise.

Pattern Detected

Recent BB-301 clinical and conference-related updates have generally coincided with positive share reactions, while the latest earnings with clinical progress saw a brief pullback.

Recent Company History

Over the last several months, Benitec has repeatedly highlighted BB-301 progress for OPMD. Positive long-term Phase 1b/2a data on Jan 11, 2026 and subsequent conference-linked updates, including a late-breaking abstract and interim results, were followed by modest to strong gains. Earnings releases in Nov 2025 and Feb 2026 paired financial updates with advancing clinical plans. Today’s MDA forum event continues this pattern of using major meetings to showcase durability and dose-response data for BB-301.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-01-30

An active S-3 resale registration dated Jan 30, 2026 covers 1,481,481 shares held by existing investors. The company will not receive proceeds from these sales but flags risks from concentrated ownership and potential resale-related stock price pressure.

Market Pulse Summary

This announcement highlighted Benitec’s BB-301 program through an industry forum at the MDA Clinical...

Analysis

This announcement highlighted Benitec’s BB-301 program through an industry forum at the MDA Clinical and Scientific Conference, emphasizing durable improvements in dysphagia and swallowing across low- and high-dose cohorts. It follows a string of positive interim and long-term Phase 1b/2a updates over recent months. Investors may watch for additional quantified efficacy data, regulatory interactions, and how increased visibility at major meetings shapes the company’s positioning within OPMD treatment development.

Key Terms

oculopharyngeal muscular dystrophy, gene therapy, dna-directed rna interference, phase 1b/2a, +3 more

7 terms

oculopharyngeal muscular dystrophy medical

"the only clinical-stage therapeutic in development for Oculopharyngeal Muscular Dystrophy (OPMD)"

A genetic muscle disorder that gradually weakens the muscles controlling eyelid movement and swallowing, often beginning in adulthood; think of it as a specific wiring fault that makes those muscle groups lose strength over time. Investors care because the condition defines a clear patient population, shapes demand for treatments, influences the size and design of clinical trials, and affects long-term healthcare costs and reimbursement decisions that drive the commercial value of therapies.

gene therapy medical

"a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

dna-directed rna interference medical

"based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform"

DNA-directed RNA interference is a biotechnology approach where a piece of DNA delivered into cells tells them to produce small RNA molecules that selectively block production of a specific protein by degrading or stopping its messenger RNA. For investors, it matters because this method can create long-lasting, highly targeted therapies for diseases — like installing a factory instruction that cuts off a problematic product — but it also carries clinical, delivery and regulatory risks that affect development timelines and potential returns.

phase 1b/2a medical

"BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) and the potential for BB-301"

Phase 1b/2a is a combined early-stage clinical study that first tests safety and optimal dosing in a small group and then expands to look for initial signs that the drug works in the target patients. Think of it as a prototype test followed by a small pilot run: it helps companies decide whether to invest in larger, more expensive trials. Investors watch these results because they reduce scientific uncertainty and can sharply affect a drug’s value and development timeline.

clinical-stage medical

"Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

dysphagic medical

"durable, improvements in dysphagic symptom burden and swallowing function experienced"

Dysphagic describes a person who has difficulty swallowing food, liquids or saliva due to problems with the muscles, nerves or structures involved in swallowing. Investors should note dysphagic status because it affects who can join clinical trials, alters safety and efficacy outcomes, and changes the size and type of patient population for treatments or devices — like a key customer group being unable to use a product.

nasdaq financial

"Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

AI-generated analysis. Not financial advice.

HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will highlight the key clinical results observed to date for OPMD Patients enrolled into the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) and the potential for BB-301 to transform the treatment landscape for patients with OPMD.

Benitec Executive Chairman and Chief Executive Officer, Jerel A. Banks, M.D., Ph.D., will share an updated presentation detailing the significant, durable, improvements in dysphagic symptom burden and swallowing function experienced by the patients treated with low dose BB-301 and high dose BB-301. The full presentation can be viewed here.

Conference attendees who are registered for the 2026 MDA Clinical and Scientific Conference are eligible to attend the Industry Forum event. Live stream is also accessible via the MDA online platform for virtually registered participants.

Details regarding the BB-301 Industry Forum Breakfast and Discussion are as follows: 
Date/Time: Tuesday, March 10, 2026, from 7:00 a.m. – 8:00 a.m. ET
Location: Hilton Orlando, Key Largo Room, 6001 Destination Parkway, Orlando, Florida 32819
Presenters: Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer, Benitec Biopharma; guest presentation by the OPMD Association

About OPMD 
There are currently no approved therapies for OPMD, a rare autosomal-dominant degenerative muscle disorder, that impacts nearly 15,000 patients in North America, Europe and Isreal. OPMD is caused by a mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene; PABPN1 is a ubiquitous protein that controls the length of mRNA poly(A) tails, mRNA export from the nucleus and alternative poly(A) site usage. OPMD is a debilitating progressive disease that weakens the pharyngeal muscles, causing severe swallowing difficulties (dysphagia).¹ Progressive dysphagia impacts 97% of OPMD patients and is a severe, life-threatening complication of OPMD which can lead to chronic choking, malnutrition, aspiration pneumonia and death.

About BB-301
BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant PABPN1 expression while providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA.

About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.

Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of pre-clinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities and other regulatory developments; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.

References:

1. https://www.mayoclinic.org/diseases-conditions/dysphagia/symptoms-causes/syc-20372028
   
   

Media Contact:
Audra Friis
Sam Brown Healthcare Communications
(917) 519-9577
audrafriis@sambrown.com

Investor Relations Contact:
Irina Koffler
LifeSci Advisors, LLC
(917) 734-7387
ikoffler@lifesciadvisors.com

FAQ

What will Benitec (BNTC) present at the MDA conference on March 10, 2026?

Benitec will present updated clinical results for BB-301, focusing on swallowing function improvements. According to the company, CEO Jerel A. Banks will detail significant, durable improvements in dysphagic symptom burden observed in low- and high-dose patients.

When and where is the Benitec BB-301 Industry Forum Breakfast for BNTC shareholders?

The Industry Forum Breakfast is on Tuesday, March 10, 2026, from 7:00–8:00 a.m. ET at the Hilton Orlando, Key Largo Room. According to Benitec, registered MDA conference attendees and virtual registrants can attend via MDA live stream.

What clinical evidence for BB-301 will Benitec (BNTC) highlight at the March 10, 2026 event?

Benitec will highlight reported significant, durable improvements in dysphagia symptom burden and swallowing function in Phase 1b/2a patients. According to the company, both low-dose and high-dose BB-301 cohorts showed these improvements to date.

Can investors who are not attending the MDA conference view Benitec's (BNTC) BB-301 presentation?

Yes. The presentation is accessible via live stream on the MDA online platform for virtually registered participants. According to Benitec, the full presentation will also be viewable through the company’s posted link for broader access.